Bioavailability study with naloxone hydrochloride in healthy volunteers

2024-517838-17-00 Protocol CVP24001 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 6 Mar 2026 · End 16 Mar 2026 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol CVP24001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 14
Countries 1
Sites 1

No therapeutic indication in the current trial with healthy volunteers.

Key facts

Sponsor
CCDRD Cooperative Clinical Drug Research and Development AG, Vaccpower Limited
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Psychiatry and Psychology [F] - Behavior and Behavior Mechanisms [F01]
Trial duration
6 Mar 2026 → 16 Mar 2026
Decision date (initial)
2026-02-10
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

No therapeutic indication in the current trial with healthy volunteers.

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

CCDRD Cooperative Clinical Drug Research and Development AG

Sponsor organisation
CCDRD Cooperative Clinical Drug Research and Development AG
Address
Dahlwitz, Lindenallee 70, Dahlwitz-Hoppegarten Lindenallee 70 Dahlwitz-Hoppegarten
City
Hoppegarten
Postcode
15366
Country
Germany

Scientific contact point

Organisation
CCDRD Cooperative Clinical Drug Research and Development AG
Contact name
Project Manager

Public contact point

Organisation
CCDRD Cooperative Clinical Drug Research and Development AG
Contact name
Project Manager

Vaccpower Limited

Sponsor organisation
Vaccpower Limited
Address
Atholl House, 29-31 Hope Street 29-31 Hope Street
City
Douglas
Postcode
IM1 1AR
Country
Isle of Man

Scientific contact point

Organisation
Vaccpower Limited
Contact name
Consultant

Public contact point

Organisation
Vaccpower Limited
Contact name
Advisor

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Bulgaria Ended 14 1
Rest of world 0

Investigational sites

Bulgaria

1 site · Ended
Bed space for short term stay at Diagnostic & Consultative Centre 'Ascendent' Ltd.
Bed space for short term stay, 47 'Bacho Kiro' str., 1202, Sofia

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Bulgaria 2026-03-06 2026-03-16

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-10-17 Bulgaria Acceptable
2026-02-06
2026-02-10